Saturday, 31 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Results Correction

Beta Drugs Results Correction

Beta Drugs submitted revised Limited Review Reports for the quarter ended June 2026, correcting the omission of UDINs as requested by the exchange.

Source

NSE filing, NSE: BETA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Beta Drugs Ltd: key numbers

Share price
₹1,798.40
Market cap
₹1,994 Cr
Revenue (annual)
₹384.8 Cr
Net profit (annual)
₹41.48 Cr
P/E (TTM)
38.4×Sector 45.9×
Promoter holding
58.91%-0.19% QoQ
FII holding
1.37%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Beta Drugs Ltd

All →

Other results correction announcements

All →